Protalix BioTherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PLX NYSE American 2836 www.protalix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protalix BioTherapeutics, Inc.

3 Penny Stocks With Market Caps Larger Than $100M To Consider - May 26th, 2026 12:05 pm
PLX: Chiesi Milestone Received - May 14th, 2026 10:55 am
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary - May 13th, 2026 6:34 pm
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... - May 13th, 2026 5:02 pm
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call - May 13th, 2026 6:19 am
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - May 13th, 2026 4:50 am
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - May 6th, 2026 4:50 am
April 2026 Penny Stocks With Promising Potential - Apr 10th, 2026 12:05 pm
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... - Mar 18th, 2026 1:00 pm
PLX: 2025 Full Year Results - Mar 18th, 2026 11:05 am
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 - Mar 18th, 2026 7:02 am
Protalix: Q4 Earnings Snapshot - Mar 18th, 2026 5:06 am
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - Mar 18th, 2026 4:50 am
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Mar 11th, 2026 4:50 am
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen - Mar 9th, 2026 8:40 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼ - Mar 9th, 2026 6:30 am
3 Promising Penny Stocks With Market Caps Up To $400M - Feb 9th, 2026 11:05 am
PLX: CHMP Delivers Positive Opinion - Feb 3rd, 2026 5:17 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - Jan 30th, 2026 7:47 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - Jan 30th, 2026 7:47 am